Bristol‑Myers Squibb posts Q3 beat, lifts 2026 revenue outlook and trims full‑year EPS guidance
Bristol‑Myers Squibb reported third‑quarter 2026 revenue of $13.1 billion, up 7% year‑over‑year, and GAAP earnings of $1.05 per share, with non‑GAAP earnings of $1.35 per share. The company raised its full‑year 2026 revenue guidance to $49.75‑$50.25 billion while lowering its adjusted EPS outlook to $6.35‑$6.55 per share, citing a $0.60‑per‑share acquisition‑related charge. Growth‑portfolio sales rose 12% to $7.7 billion, while legacy‑portfolio revenue grew 1% to $5.4 billion.
Why it matters
The higher revenue forecast signals stronger sales momentum, especially from newer drugs, which may support future cash flow. The reduced EPS guidance reflects the impact of acquisition‑related charges, lowering earnings expectations for the year.
Key facts
- 1Third‑quarter revenues increased 7% to $13.1 billion. sec.gov
- 2GAAP EPS was $1.05 and non‑GAAP EPS was $1.35 for the quarter. sec.gov
- 3Full‑year 2026 revenue guidance was raised to a range of $49.75 billion to $50.25 billion. sec.gov
- 4Full‑year adjusted EPS guidance was lowered to $6.35‑$6.55 per share, inclusive of a $(0.60) per share net impact from acquisition‑related charges. sec.gov
- 5Growth‑portfolio revenues were $7.7 billion, up 12% year‑over‑year. sec.gov
- 6Legacy‑portfolio revenues were $5.4 billion, up 1% year‑over‑year. sec.gov
Summary written by AlphAI AI Desk from 16 of 16 sources. Not investment advice. Figures are as stated by the linked sources.